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Abstract
Background: Substantial time elapses before patients with hilar cholangiocarcinoma (HCC) receive
surgical treatment because of time-consuming preoperative staging and other interventions, including
biliary drainage and portal vein embolization. Prolonged times potentially lead to unresectability and the
formation of metastases, yet these issues have not been investigated previously in HCC. This study aimed
to evaluate the time between onset of symptoms and the provision of ultimate treatment in patients with
HCC and the impact of the length of time on outcomes.
Methods: Delays in the treatment of consecutive patients with HCC were evaluated by contacting
general practitioners (GPs) and extracting data from hospital files. Time periods were correlated with
resectability, occurrence of metastasis, tumour stage and survival using logistic and Cox regression
analyses.
Results: Treatment times in 209 consecutive HCC patients were evaluated. The median time from first
GP visit until presentation at the tertiary centre was 35 days. Time until treatment was longer when initial
symptoms did not include jaundice (non-specific symptoms, P < 0.001). Duration of workup and preop-
erative biliary drainage at the tertiary centre prior to final surgical treatment resulted in an additional
median time of 74 days. No correlation was found between treatment time in weeks and resectability
[odds ratio (OR) 1.010, 95% confidence interval (CI) 0.985–1.036], metastasis (OR = 0.947, 95% CI
0.897–1.000), tumour stage (OR = 1.006, 95% CI 0.981–1.031) or survival in resected patients (hazard
ratio = 0.996, 95% CI 0.975–1.018).
Conclusions: The time that elapses between the presentation of symptoms and final treatment in
patients with HCC is substantial, especially in patients with non-specific symptoms. This time, however,
does not affect resectability, metastasis, tumour stage or survival, which suggests that preoperative
optimization should not be omitted because of potential delays in treatment.
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Introduction
Hilar cholangiocarcinoma (HCC) is a rare disease with an inci-
dence of around one case per 100 000 population, resulting in
approximately 150 new patients each year in the Netherlands.
Five-year survival rates in patients who undergo resection in
specialized centres are approaching 50%, yet the vast majority of
patients (>70%) are still ultimately unresectable. The survival of
unresectable patients is poor; median survival in this group
amounts to 1 year.1 As in all types of cancer, the prognosis of
patients with small, localized tumours is favourable compared
with that in patients with locally advanced or metastatic disease.
Theoretically, the progression of a tumour may take years before it
leads to the first symptoms and, ultimately, to metastasis.
The effect of a delay in treatment on postoperative survival has
been investigated for several more common tumours, such as
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those of breast, oesophageal, colon and prostate carcinoma.2–9
Results are conflicting: a longer time until treatment is associated
with a poor outcome in breast cancer, whereas two systematic
reviews dealing with colorectal cancer patients found no associa-
tion between length of time and survival.7–8,10 As a result of the
technically challenging surgical resection, HCC is mainly
managed in specialized tertiary centres. General practitioners
(GPs) and general referring centres rarely see these patients and,
consequently, some time may elapse before diagnosis is consid-
ered and patients are referred to an appropriate specialized centre.
In addition, rates of operative morbidity and mortality in HCC
are still considerable and thus careful selection using staging
laparoscopy,11 as well as an optimal preoperative workup, is
important. However, preoperative management may include
time-consuming interventions such as portal vein embolization
(PVE) and biliary drainage.12 The necessity of these interventions
is still under debate12–16 as many authors question whether the
advantages of the interventions outweigh the risks of tumour
progression during the period of these interventions.
In view of these issues, it was hypothesized that the delay in the
treatment of patients with HCC is longer than it is in more
common cancers, and that this delay potentially affects outcome
after surgical treatment. The aims of this study were therefore to
determine: (i) the length of time between the onset of symptoms
and the provision of ultimate treatment; (ii) the starting point of
this time to treatment [i.e. times of referrals by GPs and referring
hospitals (RHs)], and (iii) the effects of time to treatment on
resectability, metastasis, tumour stage and survival.
Materials and methods
Referral patterns and workup of patients with HCC
The Academic Medical Centre (AMC) in Amsterdam is a tertiary
referral centre for patients with HCC in the Netherlands. Most
patients are first seen in a regional hospital before they are referred
to the AMC outpatient clinic for treatment. A minority of patients
are directly referred by their GPs to AMC for clinical investiga-
tions of their symptoms. Lastly, some patients are not referred by
a GP, either because the disease is an incidental finding or because
a patient presents in person to the emergency department of a
hospital without consulting a GP. Usually some investigations
and treatments are performed in the RH, including diagnostic
imaging, cholangiography and stent placement, before patients
are referred to AMC. At AMC, staging is completed with routine
use of computed tomography, Doppler ultrasound and magnetic
resonance imaging, as described in previous reports.11,17 Each
patient is discussed in a weekly, multidisciplinary hepatopancrea-
tobiliary and oncology meeting in which a treatment plan is
designed. Factors that preclude resection at AMC have been
described previously in detail.1,11 If they were eligible for explora-
tive surgery, patients were scheduled for diagnostic laparoscopy.
Portal vein embolization was undertaken when the future liver
remnant volume was calculated to be <40% of organ size or
uptake of 99mTc-mebrofenin was <2.69%/min/m2 of body
surface area.17 Biliary drainage of at least the future liver remnant
was performed during preoperative workup when total bilirubin
was >200 mmol/l or when cholangitis occurred. In these authors’
experience, percutaneous transhepatic biliary drainage outper-
formed endoscopic biliary drainage in patients with potentially
resectable HCC, resulting in fewer infectious complications and
fewer drainage procedures.18 Although about 80% of patients
underwent biliary drainage before referral, most of them required
additional biliary drainage at AMC.18 Patients in whom no signs of
unresectability were found during either procedure were submit-
ted to resection, as described previously.11 Operative details, and
postoperative morbidity andmortality have been described earlier
in detail.1
Definition of times until surgical treatment
Patient data were retrieved from a cohort of consecutive HCC
patients seen at AMC from January 2003 to August 2010. Only
patients with a tumour arising from the biliary confluence or the
right or left main hepatic ducts were included. Patients with
tumours originating in the proximal common hepatic duct were
included if the tumour extended into the biliary confluence.
Patients who were not primarily treated at AMC and patients with
ultimately benign disease were excluded. For all patients, the GP
was contacted to obtain the date of the initial visit and details of
the presenting symptoms. Patients for whom the date of first
referral (by either the GP or the RH) could not be retrieved were
excluded from analysis because treatment time could not be cal-
culated in these patients. For all included patients, data on patient
demographics, diagnostic tests and surgery were retrieved. Infor-
mation was also obtained on the following time-points: (i) date of
first visit to the GP for initial symptoms; (ii) date of first visit to
the RH; (iii) date of first visit to the tertiary hospital (AMC), and
(iv) date of surgery.
The total time period from the initial visit of the patient to the
GP until the moment of surgery can be divided into various
intervals. The time between the initial GP visit and diagnosis at
AMC was defined as ‘treatment time’. The interval between the
initial GP visit and the first visit to the RHwas defined as ‘GP time’
and the interval between the first visit to the RH and the first visit
to AMC was defined as ‘referral time’. Lastly, the interval between
the first visit to AMC and the date of surgery was defined as
‘workup time’ (Fig. 1). Many patients are found to be unresectable
based on imaging and do not undergo laparotomy. Because these
patients have no workup time, only GP time and referral time were
used for analysis of the influence of time on resectability, metas-
tasis and tumour stage. The influence of time on survival was
analysed in resectable patients only and hence workup time was
included in the analysis in these patients.
Statistical analysis
Follow-up was recorded until October 2011 and was complete for
all but two patients. Overall survival was calculated from the date
of the first visit to AMC until the date of last follow-up or death
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according to the Kaplan–Meier method. Logistic regression was
used to calculate odds ratios (ORs) of time for resectability,metas-
tasis and tumour stage. For tumour stage, patients were stratified
according to Bismuth–Corlette (BC) type; those with BC types
I–III were compared with those with BC type IV tumours.15
Factors influencing time and the effect of time on survival were
estimated using Cox regression analysis by backward elimination.
P-values of <0.05 were considered to indicate statistical signifi-
cance. Data analyses were carried out using spss Version 18.0
(SPSS, Inc., Chicago, IL, USA).
Results
Patients and symptoms
During the period of this study, 281 HCC patients were seen at
AMC; 209 (74%) of these were eligible for inclusion in this study.
Six (2%) patients were excluded because their primary treatment
had been initiated in another hospital; another 23%were excluded
because GP data were irretrievable. This was usually because GPs
had digitalized their patient archive or because a patient had
moved to a different GP. General characteristics, referral patterns,
presenting symptoms, and operative and preoperative details are
listed in Table 1.
Treatment times
Table 2 shows GP times, referral times and workup times. One
particularly extensive GP time was caused by temporary emigra-
tion to another country after initial presentation to the GP. One
patient had been evaluated for cholestasis in the RH without signs
of malignancy almost 1 year prior to HCC diagnosis. Reasons for
longer workup times (>15 weeks) in these patients included PVE,
individual reasons, post-endoscopic retrograde cholangiopan-
creatography pancreatitis, cholangitis, difficulties in diagnosis,
evaluation of other malignancies, and the need for multiple biliary
drainage procedures. The distribution of numbers of drainage
procedures is listed in Table 1.
GP time and referral time were substantially shorter in patients
with initial symptoms of jaundice (P < 0.001) (Table 1). In par-
ticular, GP time was longer in patients who did not present with
jaundice. Most of these patients presented with atypical symp-
toms, such as abdominal complaints, elevated liver enzymes in
routine blood testing, nausea, heartburn and weight loss.
Impact of treatment time
As Table 3 shows, total time (defined as GP time + referral time)
did not affect resectability or tumour stage. In addition, in the
group comprising only patients who had undergone explorative
laparotomy, time including workup time did not affect resectabil-
ity rate or survival. Metastases were found less frequently in
patients with a longer total time [OR = 0.947, 95% confidence
interval (CI) 0.897–1.000; P = 0.051], although the difference was
not statistically significant.
In resected patients, 3- and 5-year survival rates were 60% and
52%, respectively. In multivariate analysis performed only in
resected patients, no correlation was found between survival and
time, gender, age or jaundice at initial presentation (Table 4).
Survival analysis
Treatment time analysis
First
symptoms
GP
First evaluation
at RH
Diagnosis at 
AMC
Surgery
GP time Referral time Workup time
Figure 1 Definitions of sources of time until treatment. GP, general
practitioner; RH, referring hospital; AMC, Academic Medical Centre
Table 1 Patient characteristics
General characteristics (n = 209)
Gender, male, % 64%
Age, years, median (range) 64 (29–89)
Bismuth–Corlette type, n (%)
Type I or II 28 (14%)
Type IIIa 76 (36%)
Type IIIb 38 (18%)
Type IV 67 (32%)
Referral pattern, n (%)
GP to RH to AMC 188 (90%)
RH to AMC 11 (5%)
GP to AMC 6 (3%)
AMC 4 (2%)
Presentation, n (%)
Jaundice symptoms 144 (69%)
No jaundice symptoms 63 (30%)
Unknown 2 (1%)
Operative details, n (%)
Staging laparoscopy performed 97 (46%)
Laparotomy performed 92 (44%)
Resection performed 56 (27%)
R0 resection 52 (93%)
R1 resection 4 (7%)
Preoperative details (n = 92)
Portal vein embolization performed, n (%) 6 (6%)
0 drainage procedures at AMC 25 (27%)
1 drainage procedures at AMC 25 (27%)
2 drainage procedures at AMC 20 (22%)
>2 drainage procedures at AMC 22 (24%)
GP, general practitioner; RH, referring hospital; AMC, Academic Medical
Centre.
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Discussion
This study shows that the median times between presenta-
tion to the GP and at AMC, and from presentation to the GP to
surgery were 35 days and 121 days, respectively, and that the
range of time periods across patients was wide. Referral time was
significantly shorter in patients who presented with typical
symptoms of jaundice. No significant correlation between treat-
ment time and resectability, metastasis, BC stage or survival was
found.
There have been no published reports on the impact of the
duration of the workup period on prognosis in HCC. For other
tumours, such as breast and colorectal carcinomas, this concern
has been investigated in several studies (Table 5). In some
tumours, particularly breast carcinoma, studies show a correlation
between treatment time and worse survival and advanced staging.
A large systematic review published in 1999 showed that treat-
ment time was associated with worse survival and advanced
staging in breast carcinoma.8 However, another large study found
just the opposite association. With reference to most other
tumours, no correlations between treatment time and survival
have been found. In lung carcinoma, however, three studies5,9,19
showed a correlation between shorter treatment time and
improved survival or less advanced staging. According to a recent
review, the importance of treatment time in tumour management
in general is unclear.20
Surprisingly, most of these previous studies evaluated the
impact of treatment time on survival, but not on resectability.
Although this is understandable in tumours that are usually
resectable, many tumour types render a substantial proportion of
patients unresectable. Hence, survival analysis will suffer heavily
from selection bias because patients with more aggressive
tumours are excluded. By adding resectability to the outcome
measures, the present authors aimed to achieve a more appropri-
ate evaluation particularly applicable to HCC.
In this study, no correlation between treatment time and sur-
vival or stage was apparent, yet a paradoxical trend between time
and rate of metastasis did emerge, albeit it not significant (P =
0.051). Such counterintuitive findings of a better outcome after a
longer time to treatment have been described previously in, for
example, endometrial and colorectal carcinoma.2,4,10,20–21 Differ-
ences in biological aggressiveness among tumours have been cited
as explaining this surprising finding.9,16,19,22 However, this theory is
not supported by empirical observations. Only one study looked
specifically at data indicative of biological activity, such as tumour
size, and found that patients in whom time to treatment was
longer generally had smaller tumours.10
A weakness of the present study refers to the lack of data on
patient delay (time from the start of symptoms to the patient
consulting a physician). Although this is obviously an important
source of time, recall bias renders any measurement of patient
delay susceptible to inaccuracy. Furthermore, as AMC is a tertiary
referral centre, the data used in this study are susceptible to selec-
tion bias to begin with. Patients in whom treatment time is longer
are more likely to have been investigated in a regional hospital.
Patients who are deemed to be incurable at this point are less likely
to be referred to a tertiary centre, which leads to a potential selec-
tion bias. Further, patients who became unresectable during the
workup time are not included in the survival analysis because they
were not submitted to laparotomy. Lastly, 23% of patients were
excluded because GP data were irretrievable, which may have led
Table 2 Median (first and third quartile) diagnostic times in days from first visit to the general practitioner (GP) to final treatment at Amsterdam
Academic Medical Centre (AMC)
Time All patients
(n = 209)
Jaundiced patients
(n = 144)
Patients without jaundice
(n = 63)
From seeing GP to referral to RH 7 (2–17) 6 (1–12) 18 (9–69)
From first visit to RH to first visit to AMC 25 (14–41) 22 (11–33) 36 (16–82)
Total time before visit to AMC 35 (21–69) 30 (16–45) 71 (31–154)
From first visit to AMC to surgery 74 (56–97) 75 (56–96) 74 (62–100)
RH, referring hospital.
Table 3 Correlation of treatment time in weeks and outcomes
(n = 209)
Outcome Ratio (95% CI) P-value
Resectability OR: 1.010 (0.985–1.036) 0.42
Metastasis OR: 0.947 (0.897–1.000) 0.051
Tumour stage (BC types
I–III versus IV)
OR: 1.006 (0.981–1.031) 0.67
Survival in resected patients HR: 0.996 (0.975–1.018) 0.72
95% CI, 95% confidence interval; OR, odds ratio; HR, hazard ratio; BC,
Bismuth–Corlette.
Table 4 Multivariate analysis of survival in resected patients (n = 56)
Factor Ratio (95% CI) P-value
Age OR: 0.978 (0.945–1.013) 0.22
Initial jaundice symptoms OR: 1.460 (0.546–3.904) 0.45
Treatment time (GP to
surgery)
OR: 1.004 (0.964–1.044) 0.86
Gender OR: 0.950 (0.326–2.762) 0.92
Bismuth stage OR: 0.956 (0.273–3.352) 0.94
95% CI, 95% confidence interval; OR, odds ratio; HR, hazard ratio;
GP, general practitioner.
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to a selection bias. Nonetheless, because the unavailability of GP
data usually related to GP and not to patient parameters, this bias
is deemed acceptable.
Preoperative interventions such as biliary drainage, PVE and
staging laparoscopy are used in varying degrees around the world;
however, a recent prospective series found that biliary drainage
and PVE were used in 81% and 32% of patients, respectively,23
compared with 73% and 6% of patients, respectively, at AMC.
Excellent results including mortality of 0% have been obtained
with the routine use of PVE and biliary drainage.24 However, both
interventions cause a substantial delay in treatment because PVE
adds at least another 3 weeks to this time25 and biliary drainage
also may add substantial time (to >60 days in one series14). More-
over, to facilitate optimal effects of PVE, adequate biliary drainage
of the non-embolized lobe is essential. Lastly, preoperative
interventions and particularly biliary drainage incur a risk for
complications, which include pancreatitis, cholangitis, and stent
migration or dysfunction. These complications can also consider-
ably increase time until surgical treatment. At first, the length of
workup time was surprising, but when these factors are consid-
ered, in addition to individual causes of time expenditure, this
time apparently represents the clinical reality. Furthermore, the
finding that GP time and referral time were considerably longer in
non-jaundiced patients suggests that better awareness in these
patients might facilitate the earlier detection of disease.
Differences in the lengths of time required for diagnosis and
workup in the patients in this study lay within the range of a few
months. As carcinogenesis is believed to be a process that takes
years,26 small differences in delays to treatment probably do not
affect outcome. The lack of a consistent association between treat-
ment time and prognosis, in both the literature and the current
data, suggests that treatment time has a limited impact on out-
comes. Thus, taking time to achieve optimal preoperative man-
agement seems justified.
In conclusion, the time between the presentation of symptoms
and final treatment in patients with HCC is substantial, especially
in patients with aspecific symptoms. This time, however, does not
affect resectability, metastasis, tumour stage or survival, suggest-
ing that preoperative optimization should not be omitted out of
concern that it might potentially delay treatment.
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